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Abstract
Heterozygous gain-of-kinase function variants in LRRK2 (leucine-rich repeat kinase 2) cause 1–2% of all cases of Parkinson’s 
disease (PD) albeit with incomplete and age-dependent penetrance. All pathogenic LRRK2 mutations reside within the two 
catalytic domains of LRRK2—either in its kinase domain (e.g. G2019S) with modest effect or its ROC-COR GTPase domain 
(e.g. R1441G/H) with large effect on LRRK2 kinase activity. We have previously reported assays to interrogate LRRK2 
kinase pathway activity in human bio-samples measuring phosphorylation of its endogenous substrate Rab10, that mirrors 
LRRK2 kinase activation status. Here, we isolated neutrophils from fresh peripheral blood from 101 participants including 
42 LRRK2 mutation carriers (21 with the G2019S and 21 with the R1441G mutations), 27 patients with idiopathic PD, and 
32 controls. Using a dual approach, LRRK2 dependent Rab10 phosphorylation at Threonine 73  (pRab10Thr73) was measured 
by quantitative multiplexed immunoblotting for  pRab10Thr73/total Rab10 as well as targeted mass-spectrometry for abso-
lute  pRab10Thr73 occupancy. We found a significant over fourfold increase in  pRab10Thr73 phosphorylation in carriers of the 
LRRK2 R1441G mutation irrespective of clinical disease status. The effect of the LRRK2 G2019S mutation did not reach 
statistical significance. Furthermore, we show that LRRK2 phosphorylation at Serine 935 is not a marker for LRRK2 kinase 
activity in human neutrophils. When analysing  pRab10Thr73 phosphorylation in post-mortem brain samples, we observed 
overall high variability irrespective of clinical and LRRK2 mutation status and attributed this mainly to the adverse effect of 
the peri- and post-mortem period on the stability of posttranslational modifications such as protein phosphorylation. Overall, 
in vivo LRRK2 dependent  pRab10Thr73 phosphorylation in human peripheral blood neutrophils is a specific, robust and prom-
ising biomarker for significant LRRK2 kinase hyperactivation, as with the LRRK2 R1441G mutation. Additional readouts 
and/or assays may be needed to increase sensitivity to detect modest LRRK2 kinase activation, as with the LRRK2 G2019S 
mutation. Our assays could be useful for patient stratification and target engagement studies for LRRK2 kinase inhibitors.
Keywords Parkinson’s disease · LRRK2 · LRRK2 kinase inhibitors · RabGTPases · Biomarkers · Protein phosphorylation
Introduction
Parkinson’s disease (PD) is a common neurodegenerative 
condition that affects 1% of people over the age of 60 and 
over 6 million people worldwide [5]. People with PD present 
with a wide spectrum of progressive motor and non-motor 
symptoms reflecting the relentless loss of neurons and neu-
ronal function that often predate clinical symptom onset by 
decades [20]. The greatest unmet need in PD are disease 
modifying treatments that slow or stop disease progression 
which is further highlighted by the projected doubling of PD 
cases over the next 20 years [5]. While the underlying cause 
for PD is largely unknown, the discovery of rare genetic 
forms of the condition has provided crucial insight into path-
omechanistic processes altered in PD that have been lever-
aged for devising novel targeted treatment strategies [19].
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The Leucine-rich repeat kinase 2 (LRRK2) is such a 
highly pursued therapeutic target. It is a large multidomain 
protein made up of 51 exons and 2537 amino acids with 
a predicted molecular weight of 286 kDaltons. Its cata-
lytic core is made up of a kinase and ROC-COR GTPase 
domain as well as other protein–protein interaction motifs: 
the N-terminal armadillo, ankyrin and leucine-rich repeat 
motifs and a C-terminal WD40 motif [1]. LRRK2 is highly 
expressed in immune cells including peripheral blood neu-
trophils and monocytes as well as lung, kidney and intestine 
but expression is lower in brain [24, 43]. Pathogenic variants 
in LRRK2 are a direct cause for PD albeit with age-depend-
ent and incomplete penetrance and cluster within the two 
catalytic domains of LRRK2 [6]. The substitution of serine 
for glycine at position 2019 within its kinase domain is the 
most common PD associated variant and accounts for 1% 
of sporadic and 4% of familial PD cases in most Caucasian 
populations worldwide, but up to 29% and 37% of familial 
cases in Ashkenazi Jews and North African Berbers, respec-
tively, while being largely absent in Asian populations [16, 
19, 42]. The much rarer I2020T mutation is also located in 
the LRRK2 kinase domain. The second most common muta-
tion hotspot is in the ROC-COR GTPase domain includ-
ing R1441C/G/H/S as well as N1437H and Y1699C [1]. Of 
these, the R1441G mutation is particularly common in the 
Basque region in Spain where it is responsible for 46% of all 
familial PD [26, 42]. In addition to these clearly pathogenic 
mutations, genome wide association studies have implicated 
variants at the LRRK2 locus as risk factors for idiopathic 
PD (iPD) with a modest increase in lifetime susceptibility 
for PD [30, 31].
All pathogenic LRRK2 mutations have in common that 
they augment kinase activity suggesting that inhibition of 
the LRRK2 kinase with small molecules is a promising strat-
egy for disease modification. The LRRK2 kinase domain 
mutations—G2019S and I2020T—increase LRRK2 kinase 
activity only modestly, under twofold in in vitro and in vivo 
cell and animal studies (reviewed in [40]) by domain dis-
ruption. The LRRK2 ROC and COR GTPase domain muta-
tions—N1437H, R1441 hotspot and Y1699C—suppress 
GTPases activity and promote GTP binding which in turn 
mediates a 3–4-fold increase in LRRK2 kinase activity [38, 
39]. Assessing LRRK2 kinase activation status in human 
bio-samples on the other hand has been a challenge. For 
example, while LRRK2 autophosphorylation at Serine 1292 
correlates with LRRK2 kinase activity [38], its low stoichi-
ometry makes its detection difficult and unreliable. Serine 
935 is one of the constitutively phosphorylated LRRK2 sites 
that reside in a non-catalytic region of LRRK2 and plays 
a role in 14-3-3 binding [33]. Serine 935 phosphorylation 
of LRRK2 is one of the principal pharmacodynamic mark-
ers for in vivo LRRK2 kinase inhibition [15], but not for 
LRRK2 kinase activity. More recently, the discovery of a 
subgroup of RabGTPases, including Rab10, as endogenous 
LRRK2 kinase substrates that are phosphorylated at a con-
served Threonine or Serine in conserved switch II domains 
[39], the availability of relevant tools [24] and technologies 
[21] as well as the exploration of novel biomatrices [12] has 
opened up new opportunities to assess how LRRK2 muta-
tions impinge on is kinase activity.
We have previously described a robust and facile assay for 
interrogating LRRK2 kinase pathway activity in peripheral 
blood neutrophils by quantifying LRRK2 mediated phos-
phorylation of Rab10 at Threonine 73 [11]. Phosphoryla-
tion of Rab10 at Threonine 73  (pRab10Thr73) is quantified 
by either immunoblot analysis deploying highly sensitive 
monoclonal phosphospecific antibodies raised against the 
 pRab10Thr73 epitope [11] or by a targeted mass-spectrometry 
approach [21]. As a biomatrix, peripheral blood neutrophils 
lend themselves for the study of the LRRK2 pathway as 
they constitute a homogenous and abundant pool of cells 
that contain relatively high protein copy numbers of both 
LRRK2 and Rab10 [11, 12]. We have recently utilized this 
assay to demonstrate that LRRK2 dependent  pRab10Thr73 
phosphorylation is significantly increased in PD patients 
carrying a heterozygous VPS35 D620N mutation that aug-
ments LRRK2 kinase activity by a yet unknown mechanism. 
To date elevated LRRK2 kinase pathway activation with 
LRRK2 dependent  pRab10Thr73 phosphorylation as a read-
out has not been demonstrated in bio-samples derived from 
LRRK2 mutation carriers.
In this study, we have analysed LRRK2 dependent 
 pRab10Thr73 phosphorylation as a marker for in vivo LRRK2 
activation status in human peripheral blood neutrophils 
isolated from 101 individuals including 42 LRRK2 muta-
tion carriers (21 with the G2019S mutation that resides in 
the kinase domain and 21 with the R1441G mutation that 
lies within the ROC-COR GTPase domain) with and with-
out PD and compared them with 32 healthy controls and 
27 individuals with iPD. We show that LRRK2 depend-
ent  pRab10Thr73 phosphorylation is significantly elevated 
over fourfold in all R1441G LRRKR2 mutation carriers 
irrespective of disease status while PD manifesting and 
non-manifesting G2019S mutation carriers as well as iPD 
samples lacked any such enhancement over controls. We 
deployed two independent methodologies—quantitative 
multiplexed immunoblotting for  pRab10Thr73 normalized 
against total Rab10 levels as well as targeted  pRab10Thr73 
occupancy mass-spectrometry and found relatively good 
correlation between the two assays. Furthermore, we have 
analysed brain samples derived from eight G2019S LRRK2 
and one R1441H LRRK2 mutation carriers as well as ten 
individuals with iPD and ten controls for LRRK2 dependent 
 pRab10Thr73 phosphorylation by immunoblotting. We found 
high variability amongst donors irrespective of genetic and 
disease state and concluded that post-mortem brain tissue is 
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unsuitable for analysing posttranslational modifications such 
as  pRab10Thr73 phosphorylation.
Materials and methods
A comprehensive list of reagents, antibodies, cDNA con-
structs, cell lines, buffers, equipment, software packages uti-




indazol-3-yl)pyrimidin-4-yl)morpholine (MLi-2) [13, 37] 
was synthesised at the University of Dundee and used at a 
concentration of 200 nM for a duration of 30 min for LRRK2 
kinase inhibition in the peripheral blood neutrophil experi-
ments. Diisopropylfluorophosphate (DIFP) was purchased 
from Sigma (Cat# D0879), Microcystin-LR was from Enzo 
Life Sciences and sequencing grade modified trypsin from 
Promega (Cat# V511A). Complete protease and phosphatase 
inhibitor tablets were from Roche. All heavy and light sta-
ble isotope synthetic peptides described in supplementary 
Table  1 were synthesized by JPT peptide technologies 
(https:// www. jpt. com/) in 1 nmol aliquots. All synthetic 
peptides were quantified by amino acid analysis and liquid 
chromatography–mass-spectrometry (LC–MS) analysis by 
JPT and confirmed to be of purity of > 95%. The peptides 
were delivered in a lyophilized form and were resuspended 
in solvent containing 0.1% (v/v) formic acid in 3% (v/v) 
acetonitrile to give a final concentration of 10 pmol/ml. Ali-
quots of this were further diluted in a series of tenfold dilu-
tion to a lowest concentration of 10 fmol/ml and stocks of 
each dilution aliquoted and stored at − 80 °C.
Antibodies
The recombinant MJFF-pRab10 (Thr73) rabbit monoclo-
nal antibodies were recently described in terms of their 
high selectivity and specificity [24] and is available from 
Abcam (Cat# ab230261). The MJFF-total Rab10 mouse 
antibody was from nanoTools (Cat# 0680–100/Rab10-
605B11). Rabbit monoclonal antibodies for total LRRK2 
(N-terminus, residues 100–500, UDD3) and phospho-
Ser935 LRRK2 (UDD2) as well as the sheep polyclonal 
antibodies for LRRK1 (sheep number S405C, 2nd bleed) 
were expressed and purified at the University of Dundee 
as described previously [7, 10, 25] and are available from 
MRC PPU Reagents and Services (https:// mrcpp ureag ents. 
dundee. ac. uk/). The sheep polyclonal PPM1H antibodies 
against the full length PPM1H protein have been described 
before [2] and are also available from MRC PPU Reagents 
and Services (sheep number DA018, https:// mrcpp ureag 
ents. dundee. ac. uk/). The C-terminal total LRRK2 mouse 
monoclonal antibody was from Neuromab (Cat# 75-253). 
Additionally, we used the rabbit monoclonal MJFF-pRab8 
(Thr72) (#ab230260, Abcam, Inc., [24]), mouse mono-
clonal anti-Rab8A (#WH0004218M2, Sigma–Aldrich), 
rabbit monoclonal pAMPK (Thr172) (#4188, CST), and 
mouse monoclonal total AMPK (CST, #2793) antibod-
ies. The mouse anti-GAPDH total was from Santa Cruz 
Biotechnology (Cat# sc-32233). The rabbit polyclonal 
pSer72 Rab7A was recently described and was generated 
by The Michael J. Fox Foundation’s research tools pro-
gram in partnership with Abcam [25]. Development of a 
monoclonal antibody is underway. Please contact tools@
michaeljfox.org with questions. Recombinant antibodies 
were used at 1 mg/ml final concentration for immunoblot-
ting except for anti-pRab10 (Thr73) antibody which was 
used at 0.5 μg/ml final concentration. For immunoblot-
ting applications all commercial monoclonal antibodies 
were diluted in 5% (w/v) bovine serum albumin in TBS-T 
(20 mM Tris base, 150 mM Sodium Chloride (NaCl), 
0.1% (v/v) Tween20), and sheep polyclonal antibodies 
were diluted in 5% (w/v) skimmed milk in TBS-T. Goat 
anti-mouse IRDye 800CW (Cat# 926–32,210) and IRDye 
680LT (Cat# 926-68020), goat anti-rabbit IRDye 800CW 
(Cat# 926-32211) secondary antibodies were from LICOR 
and used at 1:10,000 dilution in TBS-T.
Study participants and blood sample collection
Fresh blood was collected from a total of 101 participants; 
66 individuals were recruited via the movement disorder 
clinics at the Hospital Clinic Universitari de Barcelona 
in the fall of 2017 and 35 individuals via the Hospital 
Universitario Donostia in San Sebastian in the Basque 
region of Spain during 2019. Of the 101 participants, 42 
carried a pathogenic mutation in LRRK2–21 carried the 
G2019S mutation that resides in the kinase domain and 21 
with the R1441G mutation that lies within the ROC-COR 
GTPase domain-, 27 patients with iPD, and 32 controls. 
Demographics such as sex, age, disease duration and age at 
PD onset were collected. PD diagnosis was defined accord-
ing to the UK Brain Bank criteria with the exception that 
a positive family history for PD was not considered an 
exclusion criteria [17]. Severity of motor symptoms and 
the presence of motor complications was assessed using 
part III and IV of the Movement Disorder Society—Uni-
fied Parkinson’s disease rating scale (MDS-UPDRS-III, 
-IV) [14]. Levodopa-equivalent daily dose (LEDD) was 
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recorded as well as any additional non-oral therapies such 
as Deep Brain Stimulation (DBS). Detailed demographic 
and clinical information of all participants can be found 
in Supplementary Table 2, online resource.
Ethical approval and consent to participate
The study was approved by the respective local ethics com-
mittees. All participants gave written informed consent.
Neutrophil isolation, treatment with the specific 
LRRK2 kinase inhibitor MLi‑2 and cell lysis
Peripheral blood neutrophils were isolated directly from 
fresh blood using EasySep Direct Human Neutrophil Isola-
tion Kit (Stemcell Technologies, Cat# 19,666) based on an 
immunonegative magnetic selection process as described 
before [11, 12]. Pure and alive neutrophils were then pel-
leted by centrifugation at 335 g for 5 min and resuspended in 
20 ml RPMI 1640 media. At this stage, purified neutrophils 
were divided equally into two tubes for treatment either with 
the specific LRRK2 kinase inhibitor MLi-2 at a final concen-
tration of 200 nM or with vehicle (DMSO) for 30 min. After 
MLi-2 treatment, neutrophils were pelleted via centrifuga-
tion at 335 g for 5 min and the supernatant was carefully 
and fully removed before cell lysis in 150 µl of ice-cold lysis 
buffer [50 mM Tris/HCl, pH 7.5, 1% (v/v) Triton X-100, 
1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid (EGTA), 1 mM sodium orthovanadate, 50 
mM sodium fluoride (NaF), 0.1% (v/v) 2-mercaptoethanol, 
10 mM 2-glycerophosphate, 5 mM sodium pyrophosphate, 
1 μg/ml mycrocystin-LR (Enzo Life Sciences), 270 mM 
sucrose, 0.5 mM diisopropylfluorophosphate (DIFP) (Sigma, 
Cat# D0879) in addition to Complete EDTA-free protease 
inhibitor cocktail (Roche, Cat# 11836170001)]. Cell lysates 
were kept on ice for 10 min and then clarified by centrifuga-
tion at 20,800g for 15 min at 4 °C. Supernatants were used 
for Bradford assay (Thermo Scientific) and stored at − 80 
°C after snap freezing.
Brain sample preparation
Brain samples were obtained from institutionally approved 
autopsy collections held by the Columbia University Medi-
cal Center in New York, USA and the IDIBAPS Biobank at 
the Hospital Clinic in Barcelona, Spain.
Frozen human matched frontal (Brodmann area 9) and 
occipital (Brodmann area 17) cortex samples from nine 
individuals including three controls, three G2019S muta-
tion carriers with PD and three with iPD were obtained from 
the brain bank at the Columbia University Medical Center in 
New York. Additionally, we received 20 frontal cortex sam-
ples including seven controls, seven iPD, fife G2019S and 
one R1441H mutation carriers with PD from the IDIBAPS 
Biobank at the Hospital Clinic in Barcelona, Spain. Brain 
samples were weighed and added to a tenfold volume excess 
of ice-cold lysis buffer [50 mM Tris–HCl pH 7.5, 1% (v/v) 
Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 
50 mM sodium fluoride, 10 mM β-glycerophosphate, 5 
mM sodium pyrophosphate, 1 µg/ml microcystin-LR (Enzo 
Life Sciences), 270 mM sucrose and complete EDTA-free 
protease inhibitor cocktail (Roche, Cat # 11836170001)], 
and homogenised using POLYTRON homogenizer (KIN-
EMATICA) on ice (5 s homogenisation, 10 s interval and 5 
s homogenisation). Lysates were cleared by centrifugation 
at 20 800g for 10 min at 4 °C. Supernatants were collected, 
quantified by the Bradford assay (Thermo Scientific) and 
subjected to immunoblot analysis.
Quantitative multiplexed immunoblot analysis
Cell lysates were mixed with 4 × SDS–PAGE loading buffer 
[250 mM Tris–HCl, pH 6.8, 8% (w/v) SDS, 40% (v/v) glyc-
erol, 0.02% (w/v) Bromophenol Blue and 4% (v/v) 2-mer-
captoethanol] to a final total protein concentration of 1 µg/
µl and heated at 70 °C for 10 min. 10 µg of each sample was 
loaded onto a NuPAGE 4–12% Bis–Tris Midi Gel (Thermo 
Fisher Scientific, Cat# WG1403BOX) and electrophoresed 
at 130 V for 2 h with the NuPAGE MOPS SDS running 
buffer (Thermo Fisher Scientific, Cat# NP0001-02). At the 
end of electrophoresis, proteins were electrophoretically 
transferred onto a nitrocellulose membrane (GE Healthcare, 
Amersham Protran Supported 0.45 µm NC) at 100 V for 90 
min on ice in transfer buffer (48 mM Tris–HCl and 39 mM 
glycine). Transferred membrane was blocked with 5% (w/v) 
skim milk powder dissolved in TBS-T [20 mM Tris–HCl, 
pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at room 
temperature for 1 h. The membrane was then cropped into 
three pieces, namely the ‘top piece’ (from the top of the 
membrane to 75 kDa), the ‘middle piece’ (between 75 and 
30 kDa) and the ‘bottom piece’ (from 30 kDa to the bottom 
of the membrane). The top piece was incubated with rabbit 
anti-LRRK2 pS935 UDD2 antibody multiplexed with mouse 
anti-LRRK2 C-terminus total antibody diluted in 5% (w/v) 
skim milk powder in TBS-T to a final concentration of 1 µg/
ml for each of the antibody. The middle piece was incubated 
with mouse anti-GAPDH antibody diluted in 5% (w/v) skim 
milk powder in TBS-T to a final concentration of 50 ng/ml. 
The bottom piece was incubated with rabbit MJFF-pRAB10 
monoclonal antibody multiplexed with mouse MJFF-total 
Rab10 monoclonal antibody diluted in 2% (w/v) bovine 
serum albumin in TBS-T to a final concentration of 0.5 
µg/ml for each of the antibody. All blots were incubated 
in primary antibody overnight at 4 °C. Prior to secondary 
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antibody incubation, membranes were washed three times 
with TBS-T for 10 min each. The top and bottom pieces 
were incubated with goat anti-mouse IRDye 680LT (#926-
68020) secondary antibody multiplexed with goat anti-rabbit 
IRDye 800CW (#926-32211) secondary antibody diluted in 
TBS-T (1: 10,000 dilution) for 1 h at room temperature. The 
middle piece was incubated with goat anti-mouse IRDye 
800CW (#926-32210) secondary antibody diluted in TBS-T 
(1: 10,000 dilution) at room temperature for 1 h. Membranes 
were washed with TBS-T for three times with a 10 min incu-
bation for each wash. Membranes were scanned using the 
LICOR Odyssey CLx imaging system.
Quantification and normalization of the LICOR 
immunoblot analysis
Quantification of the protein bands was performed on the 
scanned images using the Odyssey Scan band tool in a 
blinded manner with regards to genotype and clinical sta-
tus of the participants by an independent analyst using the 
Image Studio software. Each sample set including DMSO 
and MLi-2 treated neutrophil lysates for each participant 
or each autopsy brain lysate was run in duplicates and two 
independent replicate immunoblotting experiments were 
performed and used for quantification. The intensities of the 
total LRRK2 and total Rab10 protein bands were normalized 
to that of the housekeeping protein GAPDH (total LRRK2/
GAPDH and total Rab10/GAPDH) while the specific post-
translational phosphorylation modifications were quanti-
fied against the multiplexed total target protein irrespective 
of modification (Thr73-pRab10/total Rab10 and Ser935-
pLRRK2/total LRRK2). Inter-gel variability was controlled 
for by normalization against the same control sample on 
each gel per set of experiments. In total, three sets of West-
ern blot experiments run with samples 1–66 (Barcelona 
set), samples 67–82 (San Sebastian set 1) and 83–101 (San 
Sebastian set 2) were performed at different time points. To 
combine Western blot results for all three sets of neutrophil 
lysates, results for each set were normalized to the average 
of its controls and then combined.
LC–MS/MS sample preparation
SDS–PAGE separation and in‑gel digestion
The method utilized here was adopted according to the 
recently published paper by Karayel et al. [21]. Briefly, 
neutrophil lysates were reduced with 5 mM dithiothreitol 
at 55 °C for 20 min. Samples were brought to room tem-
perature and treated with 40 mM iodoacetamide for 20 min 
in the dark. 40 μg of total soluble neutrophil protein extract 
were separated by SDS–PAGE and the gels were stained 
with colloidal Coomassie blue (Novex). Protein bands 
spanning 20–30 kDa region were excised, destained with 
40% (v/v) acetonitrile in 40 mM ammonium bicarbonate on 
a Thermomixer for 20 min at room temperature. Destain-
ing solution was discarded and this step was repeated once, 
until gel pieces were completely destained. Gel pieces were 
dehydrated with 100% acetonitrile on a Thermomixer for 15 
min at room temperature, followed by complete removal and 
placing of the tubes on ice. The dried gel pieces were res-
wollen in 150 μl of 20 mM triethylammonium bicarbonate 
buffer (TEABC) pH7.5 containing 500 ng of sequencing 
grade modified trypsin and 0.1% (w/v) sodium deoxycho-
late. Samples were incubated at 37 °C for 16 h. Peptides 
were extracted by adding 70 μl of 0.5% acetic acid (v/v) in 
80% (v/v) acetonitrile to samples and incubated on a shaker 
for 15 min at room temperature. The liquid containing the 
peptide extraction was then transferred into a fresh tube. 
The extraction step was repeated twice with pooling of the 
peptide solutions with that of the previous step. Peptide solu-
tions were snap frozen with dry ice and dried in a Speedvac 
evaporator.
SDB‑RP (Styrenedivinylbenzene—Reversed Phase) 
purification
SDB-RP tips were prepared in-house by punching two layers 
of SDB-RP disks using a 16 gauge syringe needle, which 
were then pushed into a 250 µl pipette tip. Vacuum dried 
peptides from the previous step were reconstituted with 100 
µl of 1% (v/v) trifluoroacetic acid in isopropanol and directly 
loaded on SDB-RP tips. Samples were centrifuged at 1500g 
for 10 min at room temperature to allow binding of peptides 
onto the disks. Flowthrough was collected and reloaded onto 
stage tips for another round of binding. Subsequently, stage 
tips were washed twice with 100 µl of 1% (v/v) trifluoro-
acetic acid in isopropanol, and then with 100 µl of 0.2% (v/v) 
trifluroacetic acid in 3% (v/v) acetonitrile. Wash steps were 
undertaken by centrifugation at 2000g for 6 min at room 
temperature and the flowthrough was discarded. Peptides 
were eluted sequentially with freshly prepared 1.25% (v/v) 
ammonium hydroxide in 50% (v/v) acetonitrile and 1.25% 
(v/v) ammonium hydroxide in 80% (v/v) acetonitrile. Puri-
fied peptides were snap frozen with dry ice and dried in a 
Speedvac evaporator.
Spike in of heavy‑labelled peptides and sample loading 
on Evotips
Sample loading on Evotips was performed as described 
previously [2] with minor modifications as described 
below. Vacuum dried peptides were reconstituted in 80 µl 
of 0.1% (v/v) formic acid in 3% (v/v) acetonitrile buffer 
and allowed to dissolve at room temperature for 10 min. To 
calculate absolute phosphorylated  pRab10Thr73 occupancy, 
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an equimolar mixture of 25 fmol of heavy stable isotope-
labelled (SIL) phosphorylated and non-phosphorylated 
Rab10 counterpart peptides and 25 fmol of PRTC retention 
time calibration mix were spiked in. The peptide sample mix 
was then subjected to sonication in a water bath sonicator 
(Branson) for 10 min and centrifuged at 17,000g at room 
temperature for 10 min. Evotips (EvoSep, Cat #EV2001) 
were activated by adding 20 µl of buffer B [100% (v/v) ace-
tonitrile in 0.1% (v/v) formic acid] and centrifuged at 800g 
for 1 min. Tips were immersed into 200 µl of isopropanol 
and then equilibrated by adding 20 µl of buffer A [0.1% (v/v) 
formic acid in water] and centrifuging at 800g for 1 min. 
This step was repeated one more time. Peptides were loaded 
on Evotips using gel loading tips and centrifuged at 700g for 
5 min. The flowthrough was collected, reapplied and centri-
fuged. Next, the tips were washed twice with buffer A. 100 
µl of buffer A was applied to the Evotips which were then 
placed on the autosampler tray of EvoSep LC system.
Parallel reaction monitoring (PRM) measurements
All of the targeted LC–MS/MS (PRM) data were acquired 
on QE HF-X Mass spectrometer interfaced in line with an 
EvoSep liquid chromatography (LC) system. EvoTips were 
loaded on EvoSep LC system autosampler tray and analysed 
using a 21 min (60 samples per day) script. The EvoSep 
LC system elutes peptides by applying a partial gradient 
using low pressure pump-A and B into the long storage cap-
illary sample loop where peptides were partially stored and 
focused by pre-formed gradient using low pressure pump-
C and pump-D. Peptides were subsequently directed to an 
analytical column (Reprosil-pur C18 AQ, 3 µm beads, 100 
µm ID, 8 cm long for pRab analysis) by high pressure pump 
which is housed into the Easy nano source. Peptides were 
then directly electrosprayed into the mass spectrometer by 
maintaining 2000 voltage. Mass spectrometer was operated 
in a targeted PRM mode by employing one full MS scan 
followed by a PRM scan which is instructed to operate by 
following the imported inclusion list with a scheduled reten-
tion time (peptide sequences and m/z values are provided in 
supplementary table 1). Dynamic on-the-fly retention time 
correction was enabled to correct the scheduled retention 
time. Full MS scan was acquired within 300–800 m/z and 
acquired at 120,000 resolution at 200 m/z using Orbitrap 
mass analyser. Each of the targeted analytes was isolated 
using Quadrupole mass filter with a 0.7 Da isolation window 
and fragmented using normalized 27% higher energy colli-
sional dissociation (HCD) and measured at 30,000 resolution 
at 200 m/z using Orbitrap mass analyser. The loop cycle was 
maintained at ten scan per duty cycle. The automatic gain 
control (AGC) targets for full MS and PRM were at 3E6 and 
1E5 ions, respectively, and a maximum of 50 ms for MS1 
and 300 ms for PRM scan. For the limit of detection (LOD) 
experiments (Fig. 1b), the heavy pRab10 peptide was kept at 
a constant amount of 50 fmol and the light pRab10 peptide 
varied from (0.01, 0.1, 1, 10, 50 and 200 fmol), directly 
spiked into 50 ng HeLa cell tryptic digest. PRM data were 
acquired as described above except the ion injection times 
for 0.01, 0.1 and 1 fmol data were maintained at 500 ms.
Spectral library generation
The retention times of heavy stable peptides were deter-
mined using an equimolar mixture of 50 fmol and 25 fmol 
of PRTC peptide mixture was acquired using data dependent 
acquisition (DDA) mode on QE HF-X mass spectrometer 
in line with the EvoSep LC system. The DDA data were 
acquired using one full MS and 10 top N MS2 scans by 
disabling dynamic exclusion option. MS1 and MS2 scans 
were acquired at 120,000 and 30,000 resolution at 200 m/z 
and measured using Orbitrap mass analyser. Raw data were 
processed using Proteome Discoverer v2.2 using Sequest 
search algorithm against Uniprot Human proteome database 
that was appended with PRTC peptide sequences. Mass 
error tolerance was set for MS1 at 10 ppm and 0.05 Da for 
MS2. Carbamidomethylation of Cys as a fixed modification 
and heavy label (13C6 15N4) for Arg and (13C6 15N2) for Lys 
residues, phosphorylation of Ser/Thr were set as dynamic 
modification. Percolator node was used to filter that data at 
1% FDR. The output.msf files were directly imported into 
Skyline software suite to serve as a spectral library which 
was then used for all of the subsequent human neutrophils 
PRM data.
MS data analysis and phosphorylation occupancy 
calculations
All of the PRM raw data were imported into Skyline soft-
ware suite. An In-house generated spectral library was used 
to pick the precursor and top six fragment ions. Both double 
(z = 2) and triple (z = 3) charge states were used. Extracted 
ion chromatograms of both MS1 and MS2 fragment transi-
tions were manually examined and adjusted for any inter-
fering ions. The light/heavy internal standard ratio values 
were exported to calculate the  pRab10Thr73 occupancy 
as described before [21]. Briefly, the  pRab10Thr73 occu-
pancy was calculated by taking the ratio of total amount 
of phosphorylation to the total amount of both phosphoryl-
ated and non-phosphorylated ratio that was represented in 
terms of percentage, [pRab10 L/H/pRab10 L/H + npRab10 
L/H × 100]. All of the neutrophil samples phosphorylation 




All of the proteomics mass spectrometry raw data and data-
base search result output files have been submitted to Pro-
teomeXchange consortium (http:// prote omece ntral. prote 
omexc hange. org) via the PRIDE repository. The data can 
be accessed with the following identifier (PXD024898) [36].
Statistical analysis
Bioinformatic analyses in this study were performed with 
Skyline (https:// skyli ne. ms/ proje ct/ home/ softw are/ Skyli ne/ 
begin. view), Microsoft Excel and Graphpad Prism (Graph-
Pad Software). Data visualization was done using GraphPad 
Prism (GraphPad Software). In general, grouped data analy-
sis was performed using one-way ANOVA for multiple com-
parisons or unpaired t-test and displayed graphically using 
GraphPad Prism software (version 9).
Results
Clinical cohort and peripheral blood collection
A total of 101 participants were recruited, 66 individuals via 
the movement disorder clinics at Hospital Clinic Universitari 
de Barcelona and 35 individuals via the Hospital Universi-
tario Donostia in San Sebastian. Of the 101 participants, 
42 carried a pathogenic mutation in LRRK2-21 carried the 
G2019S mutation that resides in the kinase domain and 21 
with the R1441G mutation that lies within the ROC-COR 
GTPase domain—, 27 patients with iPD, and 32 controls 
(Table 1). Amongst the LRRK2 mutation carriers were 
individuals with and without PD. In keeping with the age-
dependent penetrance of LRRK2, non-manifesting mutation 
carriers tended to be younger than those with PD. All par-
ticipants were clinically evaluated for PD motor symptoms 
and motor complications using the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS) parts III and IV and age at onset 
of PD and PD duration as well as L-dopa equivalent daily 
dose (LEDD) calculated where applicable (Supplementary 
table 2, online resource). 20 ml of fresh peripheral blood 
was collected for immediate neutrophil isolation followed by 
ex vivo neutrophil treatment with and without the specific 
LRRK2 kinase inhibitor MLi-2 (200 nM, 30 min) prior to 
cell lysis and snap freezing for storage at − 80 °C.
All procedures were performed in compliance with the 
local ethics review boards and all participants provided 
informed consent.
Experimental design and workflow
The experimental design and statistical analysis for each 
experiment are described in each subsection and figure leg-
end. Briefly, all peripheral blood neutrophil samples isolated 
from participants were subjected to duplicate quantitative 
multiplex immunoblotting as well as mass-spectrometry 
with technical replicates per analysis (≥ 2) (Fig. 1). Analysis 
was performed blinded—in case of the quantitative immu-
noblotting by independent analysis and in case of the mass-
spectrometry with genotype and clinical status only revealed 
Table 1  Summary of demographic and clinical characteristics of participants (n = 101)
Of the 101 participants, 42 carried either the LRRK2 kinase domain mutation G2019S or the ROC-COR GTPase domain mutation R1441G and 
were either diagnosed with PD or non-manifesting mutation carriers (NMC). Mean age in years (y) and age range in parenthesis, mean disease 
duration in years with range in parenthesis
UPDRS Unified Parkinson’s Disease Rating Scale, part III (motor symptoms) in the on state and part IV (motor complications), LEDD l-dopa 
equivalent daily dosage in mg
LRRK2 mutation carriers (n = 42) iPD Controls
G2019S (n = 21) R1441G (n = 21)
Clinical manifestation (PD/NMC)
G2019S-PD G2019S-NMC R1441G-PD R1441G-NMC
(n = 12) (n = 9) (n = 13) (n = 8) (n = 27) (n = 32)
Age, y 53 (33, 73) 51 (37,69) 59 (42, 78) 58 (49, 85) 68 (53, 80) 60 (40, 82)
Age at onset, y 55 (33, 81) – 60 (44, 78) – 60 (37, 78) –
Disease duration, y 9 – 9 – 8 –
UPDRS Part III (on) 17 – 22 – 19 –
UPDRS IV 4 – 2 – 2 –
LEDD (mg) 580 – 597 – 738 –
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after the mass-spectrometry measurements were completed. 
To demonstrate that the phosphorylation of Rab10 at Threo-
nine 73 was mediated by the LRRK2 kinase, neutrophils 
were treated with and without the specific LRRK2 kinase 
inhibitor MLi-2.
Sensitivity and specificity of the LRRK2 inhibitor 
MLi‑2 in human peripheral blood neutrophils
The aim for using the LRRK2 kinase inhibitor MLi-2 at 
a concentration of 200 nM was to achieve near complete 
dephosphorylation of Rab10 at the LRRK2 dependent 
phosphoepitope Threonine 73. Dose–response studies of 
MLi-2 in human peripheral blood neutrophils derived from 
two healthy donors demonstrated as before [11] that 50% 
SDS-PAGE gel enrichment 
of 30-20kDa region
Study cohort (n=101)
Fresh peripheral blood collection
32 Controls21 LRRK2 G2019S 21 LRRK2 R1441G 27 idiopathic PD
Quantitative multiplex Western blotting
• pRab10Thr73 / total Rab10
• pSer935 LRRK2 / total LRRK2
Immunomagnetic negative peripheral blood neutrophil isolation





Targeted quantitative high-resolution mass-spectrometry
in PRM-mode for identification and quantification of 
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Fig. 1  Experimental design and workflow for peripheral blood 
neutrophils. a 20 ml of fresh peripheral blood was collected from 
101 participants with and without either PD and with or with-
out  a pathogenic LRRK2 mutation—LRRK2 G2019S or LRRK2 
R1441G—for peripheral blood neutrophil isolation by immunomag-
netic negative isolation. Purified neutrophils were then split into two 
parts for ex  vivo treatment with either the specific LRRK2 kinase 
inhibitor MLi-2 (200 nM) or DMSO for 30 min prior to cell lysis and 
storage at -80 degrees Celsius. All sets of neutrophil lysates (MLi-2 
and DMSO treated) were then subjected to quantitative multiplexed 
immunoblotting for  pRab10Thr73 phosphorylation/total Rab10 protein 
ratio as well as targeted mass-spectrometry for  pRab10Thr73 phospho-
rylation occupancy with spike in of heavy-labelled Rab10-phospho- 
and total peptide standards after enrichment by SDS–PAGE followed 
by in-gel digestion and subsequent mass-spectrometry and data analy-
sis. Additionally, quantitative immunoblot analysis was performed 
for Serine 935 phosphorylation/ total LRRK2 protein as well as 
total Rab10 and total LRRK2 protein levels, both normalised against 
GAPDH. Limit of detection of targeted MS assay (b). Scatter plot 
depicting the limit of detection and quantification of  pRab10Thr73 in 
targeted PRM. 50 fmol of heavy  pRab10Thr73 was mixed with a vari-
able amount of light pRab10 ranging from 0.01, 0.1, 1, 10, 50, 100 
and 200 fmol that was spiked into 50 ng of HeLa lyastes. Light/heavy 
ratio values were plotted to show the linear response of  pRab10Thr73 
[0.01 to 200 fmol (R2 = 0.9943)). The zoom in rectangular box depict-




reduction in phosphorylation was achieved at a dose of 30 
nM and a suppression of Rab10 phosphorylation to near 
basal levels at doses of 100 nM and above (suppl. Figure 1, 
online resource). A similar dose response was previously 
observed using another phospho-antibody with broader 
specificity for LRRK2 dependent phosphorylation of the 
endogenous Rab proteins Rab8A, Rab10 and Rab35 [23]. 
Additionally, we show that MLi-2 at a concentration of up 
to 300 nM does not result in dephosphorylation of Rab7a, 
the endogenous phosphorylation substrate of the only known 
LRRK2 homologue LRRK1 [25] or dephosphorylation 
of AMPK at threonine 172. Serine 935 dephosphoryla-
tion of LRRK2 is seen at maximal levels starting at 100 
nM MLi-2 and above. Total levels of LRRK2, LRRK1 and 
AMPK did not change (suppl. Figure 1, online resource).
LRRK2 R1441G mutation carrier status significantly 
augments LRRK2 dependent  pRab10Thr73 
phosphorylation in neutrophils derived from PD 
manifesting and non‑manifesting individuals
We analysed LRRK2 dependent phosphorylation of 
 pRab10Thr73 in peripheral blood neutrophils from 42 LRRK2 
mutation carriers in comparison to 32 controls as well as 
27 iPD patients. Peripheral blood neutrophils were isolated 
from fresh blood by immunomagnetic negative selection as 
previously described [12]. Prior to cell lysis neutrophils were 
split in half and treated with and without the specific LRRK2 
kinase inhibitor MLi-2 to demonstrate that  pRab10Thr73 
phosphorylation is mediated by the LRRK2 kinase. When 
analysed by quantitative multiplex immunoblotting, we 
observed a striking 4.5-fold increase in LRRK2 dependent 
 pRab10Thr73 phosphorylation in R1441G mutation carriers 
compared to controls, iPD and G2019S mutation carriers 
(Fig. 2a). When segregated according to clinical disease 
status,  pRab10Thr73 phosphorylation status was equally 
augmented in PD manifesting as well as non-manifesting 
individuals with R1441G positive mutation status (Fig. 2a 
and Tables 2, 3). There was no statistically significant differ-
ence in  pRab10Thr73 phosphorylation levels in G2019S muta-
tion carriers irrespective of disease status and also not in 
iPD patients when compared to controls or with each other. 
Total Rab10 levels were remarkable consistent amongst par-
ticipants and did not differ between the groups (Fig. 2b). A 
representative result of one technical replicate with duplicate 
loading for both DMSO and MLi-2 treated samples of the 
immunoblot analysis of all 101 participants is shown in Sup-
plementary Fig. 2, online resource. This also clearly shows 
the LRRK2 dependency of the  pRab10Thr73 phosphoryla-
tion signal with significant reduction in the LRRK2 kinase 
inhibitor treated samples of all participants when compared 
to DMSO.  
Fig. 2  LRRK2 R1441G mutation  carrier status significantly aug-
ments LRRK2 dependent pRab10Thr73 phosphorylation in neu-
trophils derived from PD manifesting and non-manifesting indi-
viduals. a Grouped analysis of  pRab10Thr73 phosphorylation levels 
obtained by multiplexed immunoblotting with MJFF-pRAB10 mon-
oclonal antibodies against the LRRK2 phosphorylated Rab10 phos-
phoepitope Threonine 73 normalized to the total Rab10 protein levels 
of DMSO treated neutrophil lysates and to the average of the respec-
tive controls. Bars depict group means and standard deviation (SD). 
Quantifications were based on the average value of at least two inde-
pendent immunoblot runs with duplicate loading. The LRRK2 muta-
tion carrier groups were further broken down by clinical disease sta-
tus—either PD manifesting (PD) or non-manifesting carriers (NMC). 
Differences between groups were calculated by one-way ANOVA fol-
lowed by multiple comparisons where the mean of each column was 
compared against the mean of the control group. ****p < 0.0001. b 
Total Rab10 protein levels normalized against the housekeeping pro-
tein GAPDH (mean and SD)
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Positive correlation between Western blotting 
and targeted mass‑spectrometry assays for LRRK2 
dependent  pRab10Thr73 phosphorylation
In parallel to quantitative immunoblotting for  pRab10Thr73 
phosphorylation, the neutrophil samples were subjected to 
an ultra-sensitive targeted mass-spectrometry (MS) based 
Table 2  Quantification of  pRab10Thr73 phosphorylation levels by 
immunoblotting and targeted mass-spectrometry—descriptive analy-
sis of multiplexed immunoblotting of  pRab10Thr73/total Rab10 ratio 
normalized to healthy control DMSO neutrophil samples of at least 
two independent experiments with duplicate loading (≥ 4 data points 
per sample) and targeted mass-spectrometry measuring absolute 
 pRab10Thr73 occupancy (%) of two independent measurements includ-
ing mean, standard deviation (SD), minimum and maximum for con-
trol, iPD and LRRK2 G2019S and R1441G mutation carriers
Segregation of LRRK2 mutation carriers according to clinical status did not reveal a statistical difference between mutation carriers with and 
without PD using unpaired t testing (PD vs NMC for LRRK2 G2019S and R1441G) but was not included in this table
Multiplex immunoblotting normalized pRab10/
total Rab10 (DMSO)
Controls (n = 32) iPD (n = 26) G2019S (n = 21) R1441G 
(n = 20)
Mean (ratio) 1.00 0.94 1.06 4.61
SD 0.40 0.37 0.20 1.70
Minimum 0.11 0.21 0.53 1.80
Maximum 2.01 1.78 1.58 8.16
Targeted mass-spectrometry pRab10 (DMSO) 
occupancy
(n = 32) (n = 26) (n = 21) (n = 20)
Mean (%) 1.52 1.61 1.90 6.60
SD 0.67 0.65 0.40 2.39
Minimum 0.20 0.20 1.01 2.85
Maximum 3.21 3.22 2.61 12.90
Table 3  Quantification of  pRab10Thr73 phosphorylation levels by 
immunoblotting and targeted mass-spectrometry—one-way ANOVA 
followed by Tukey’s multiple comparisons where the LRRK2 
dependent  pRab10Thr73 phosphorylation signal for each group was 
compared against all other groups as well as DMSO vs. MLi-2 treated 
samples per group including adjusted p value, mean difference and 
95% confidence interval of difference
For the immunoblotting analysis it is important to note that results are normalized against the means of controls for the three separate sets of 




Multiplex immunoblotting: normalized pRab10/total 
Rab10
Targeted mass-spectrometry: pRab10 occupancy (%)
Summary Adj. p 
value
Mean diff 95.00% CI of diff Summary Adj. p 
value
Mean diff 95.00% CI of diff
Control DMSO vs. iPD 
DMSO
ns  > 0.9999 0.06  − 0.4656 to 0.5851 ns  > 0.9999  − 0.0872  − 0.7808 to 0.6064
Control DMSO vs. G2019S 
DMSO
ns  > 0.9999  − 0.06  − 0.6140 to 0.5036 ns 0.7636  − 0.3795  − 1.117 to 0.3583
Control DMSO vs. R1441G 
DMSO
****  < 0.0001  − 3.61  − 4.177 to − 3.043 ****  < 0.0001  − 5.073  − 5.822 to − 4.325
iPD DMSO vs. G2019S 
DMSO
ns 1.00  − 0.11  − 0.6987 to 0.4689 ns 0.9414  − 0.2923  − 1.063 to 0.4785
iPD DMSO vs. R1441G 
DMSO
****  < 0.0001  − 3.67  − 4.262 to − 3.078 ****  < 0.0001  − 4.986  − 5.768 to − 4.205
G2019S DMSO vs. R1441G 
DMSO
****  < 0.0001  − 3.56  − 4.177 to − 2.933 ****  < 0.0001  − 4.694  − 5.515 to − 3.873
Control (DMSO vs. MLi-2) ns  > 0.9999 0.00  − 0.4975 to 0.4975 ****  < 0.0001 1.224 0.5669 to 1.880
iPD (DMSO vs. MLi-2) ns  > 0.9999  − 0.02  − 0.5675 to 0.5362 ****  < 0.0001 1.361 0.6251 to 2.097
G2019S (DMSO vs. MLi-2) ns  > 0.9999  − 0.03  − 0.6421 to 0.5861 ****  < 0.0001 1.626 0.8158 to 2.437
R1441G (DMSO vs. MLi-2) ****  < 0.0001 3.62 2.994 to 4.252 ****  < 0.0001 6.331 5.490 to 7.173
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assay for analysing  pRab10Thr73 phosphorylation occupancy 
with spike in of synthetic stable isotope-labelled (SIL) tryp-
tic Rab 10 peptides around the Threonine 73 epitope in its 
phosphorylated as well as unphosphorylated form as internal 
standards [21] (Fig. 1). This analysis allowed us to address 
reproducibility of our immunoblotting results by an inde-
pendent method, correlation between the two assays and 
importantly explore whether a potentially more sensitive 
analysis by mass-spectrometry could yield a statistically 
significant difference in  pRab10Thr73 phosphorylation levels 
for the G2019S mutation carrier group or iPD patients when 
compared to controls.
We measured  pRab10Thr73 phosphorylation occupan-
cies in all MLi-2 treated and untreated (DMSO) neutrophil 
samples from all 101 participants (Fig. 3a). Consistent with 
immunoblotting data, the average  pRab10Thr73 occupancy 
in the control group was 1.52% whereas it increased over 
fourfold to 6.60% in the R1441G mutation carrier group 
(p < 0.0001, one-way Anova). Here again, the MS assay 
confirmed that there was no significant difference between 
control group occupancies in comparison to the iPD (1.61%) 
and G2019S mutation carrier groups (1.90%) (Tables 2, 3). 
Furthermore, when LRRK2 mutation carriers were sepa-
rated by clinical PD status and analysed by unpaired t-test 
there was also no difference between R1441G-PD manifest-
ing and non-manifesting individuals (p = 0.23) or between 
G2019S-PD manifesting and non-manifesting individuals 
(p = 0.33) (Fig. 3a and Table 3). Figure 3a also shows the 
respective  pRab10Thr73 phosphorylation occupancies in the 
LRRK2 kinase inhibitor treated samples (MLi-2) which 
was significantly reduced when compared to the untreated 
(DMSO) samples for each group (p < 0.0001, Table 3) and, 
therefore, clearly demonstrating that the phosphorylation of 
 pRab10Thr73 is mediated by the LRRK2 kinase. As with the 
analysis by Western blotting, mass-spectrometry analysis 
for total Rab10 levels did not significantly differ between 
the groups (Fig. 3b).
While the targeted  pRab10Thr73 phosphorylation mass-
spectrometry analysis of our neutrophil samples indepen-
dently confirmed that neutrophils from LRRK2 R1441G, 
but not G2019S mutation carriers or patients with iPD have 
significantly elevated LRRK2 dependent Rab10 phospho-
rylation levels, we were interested in directly comparing 
the results obtained by the two methods. We, therefore, 
aligned the MS and WB data per individual (Fig. 4a, b) and 
found good correlation between the two methods (R2 = 0.78, 
p < 0.0001) (Fig. 4c). Representative results are shown in 
Fig. 5 where duplicate DMSO and MLi-2 treated neutrophil 
samples from the same 10 individuals including five con-
trols and five R1441G mutation carriers were analysed for 
 pRab10Thr73 phosphorylation levels by quantitative Western 
blotting (Fig. 5a) and targeted  pRab10Thr73 mass-spectrome-
try (Fig. 5b). The data also clearly show that the  pRab10Thr73  
phosphorylation signal was significantly reduced to almost 
undetectable levels when neutrophils were treated with the 
specific LRRK2 kinase inhibitor MLi-2 confirming the 
specificity of the  pRab10Thr73 phosphorylation signal as a 
substrate of the LRRK2 kinase in this cell type. 
Fig. 3  Significantly elevated pRab10Thr73 phosphorylation occu-
pancy in neutrophils derived from R1441G mutation carriers 
with and without PD. a Quantification of  pRab10Thr73 occupancy 
(%) in DMSO and MLi-2 treated neutrophil lysates derived from 
controls, iPD and LRRK2 mutation carriers of either the G2019S or 
R1441G mutation. PD or non-manifesting carriers (NMC) status indi-
cated in DMSO samples by colour. One-way ANOVA with multiple 
comparisons was applied with the mean of each column being com-
pared with the mean of the control group.  pRab10Thr73 occupancy is 
presented as means ± SD. ****p < 0.000. There was no statistically 
significant difference between manifesting and NMC carriers for both 
R1441G and G2019S mutations (see also Table 2). b Peak areas of 
endogenous total Rab10 (two peptides) were summed and normalized 
to median intensity displayed with mean and SD. Proteomic analysis 
of total Rab10 peptide levels did not differ between groups
 Acta Neuropathologica
1 3
Biological sex did not impact on LRRK2 dependent 
 pRab10Thr73 phosphorylation
As male and female sex is an important determinant for 
PD susceptibility, we assessed the effect of sex on LRRK2 
dependent  pRab10Thr73 phosphorylation in neutrophils. 
Overall, there was no significant difference in  pRab10Thr73 
phosphorylation occupancies between male and female 
participants (data not shown) and also no significant dif-
ference when each group including controls, iPD, G2019S 
and R1441G mutation carriers was segregated by sex (Sup-
plementary Fig. 4, online resource).
LRRK2 total protein and LRRK2 Serine 935 
phosphorylation levels in peripheral blood 
neutrophils
In addition to phosphorylated and total Rab10 levels, we 
analysed Serine 935 phosphorylation of LRRK2 and total 
LRRK2 levels by quantitative Western blotting in all periph-
eral blood neutrophil samples. We observed a small, but sta-
tistically significant reduction in Serine 935 phosphorylation 
Fig. 4  Good correlation between quantitative multiplexed phos-
phorylated Rab10Thr73/total Rab10 immunoblotting and targeted 
pRab10Thr73 occupancy assays in peripheral blood neutrophils. a 
 pRab10Thr73 phosphorylation occupancies in DMSO treated neutro-
phils per individual arranged in descending order by group (b) and 
aligned quantitative immunoblotting analysis of  pRab10Thr73/total 
Rab10 ratios (b) were plotted as mean with SD for all 101 partici-
pants. c Pearson correlation between immunoblotting for  pRab10Thr73 
phosphorylation/total Rab10 protein levels and targeted  pRab10Thr73 
occupancies. Blotted are mean values of two independent experi-
ments for each method (R2 = 0.78, p < 0.0001)
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of LRRK2 in R1441G mutation carriers when compared 
to iPD (p = 0.045), but no difference when compared to 
G2019S mutation carriers or controls (Fig. 6a). This is con-
sistent with previous work that has revealed that the R1441G 
mutation reduces Serine 935 phosphorylation [33, 40]. 
When Serine 935 phosphorylation levels were compared 
between R1441G mutation carriers with and without PD, 
there was no difference (p = 0.99). We also did not find a 
statistically significant reduction of Serine 935 phosphoryla-
tion of LRRK2 in G2019S mutation carriers irrespective of 
disease status when compared to iPD or in fact any of the 
other groups. LRRK2 total protein levels did not signifi-
cantly differ between the R1441G mutation carriers, G2019S 
mutation carriers, iPD and controls (Fig. 6b).
pRab10Thr73 phosphorylation in human 
post‑mortem brain samples
PD is considered a condition of the central nervous system 
and an important question is how the analysis of LRRK2 
dependent  pRab10Thr73 phosphorylation in human peripheral 
blood neutrophils compares to the analysis of pRab10 Thr73 
phosphorylation and LRRK2 levels in the brain. To address 
this, we obtained matched frontal and occipital cortex sam-
ples from 9  individuals including 3 controls, 3 G2019S 
mutation carriers with PD and 3 iPD from the brain bank 
at the Columbia University Medical Center in New York. 
Additionally, we were able to access 20 frontal cortex sam-
ples including 7 controls, 7 iPD, 5 G2019S and 1 R1441H 
mutation carriers with PD from the IDIBAPS Biobank 
at the Hospital Clinic in Barcelona, Spain. Demographic 
and clinical information is provided in Supplementary 
table 3, online resource. We used multiplexed quantitative 
Fig. 5  Representative results for five controls and five R1441G 
mutation carriers. a Immunoblotting of neutrophils isolated 
from five R1441G LRRK2 mutation carriers with PD (n = 2) and 
non-manifesting carrier status (n = 3) as well as five controls with 
duplicate loading of 10 µg of DMSO and MLi-2 (200 nM MLi-
2, 30 min) treated whole cell extracts using antibodies against total 
LRRK2, pSer935 LRRK2, total Rab10, MJFF-pRAB10 (pThr73) 
and GAPDH. (b) Quantification of immunoblots of two independent 
experiments by analysing  pRab10Thr73 /total Rab10 ratio of DMSO 
treated samples b per individual and c per group with group differ-
ence calculated by unpaired t test (***p = 0.0007). d The respective 
summed intensities of fragment ion transitions are represented with 
different colours as shown in the bottom panel of the graph. e Rela-
tive endogenous pRab10 peak areas of two independent analysis for 
 pRab10Thr73 occupancy depicted as a bar graph for DMSO and MLi-2 
treated samples of all ten participants and f per group with group dif-
ference calculated by unpaired t test (**p = 0.0014)
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immunoblotting (suppl. Figure 4, online resource) to assess 
 pRab10Thr73 phosphorylation against total Rab10 levels and 
LRRK2 Serine 935 phosphorylation against total LRRK2. 
Total protein levels for Rab10 and LRRK2 were measured 
by normalization against a housekeeping protein. With 
regards to  pRab10Thr73 phosphorylation, we observed high 
variability amongst samples from low to almost undetect-
able levels in the majority of samples and very high levels 
in some irrespective of group or LRRK2 mutation status; in 
fact, some of the highest  pRab10Thr73 phosphorylation lev-
els were observed amongst the control samples. Also, the 
LRRK2 R1441H genotype, which is as R1441G another hot-
spot mutation at the R1441 site and known to significantly 
augment LRRK2 dependent  pRab10Thr73 phosphorylation 
in the heterologous overexpression system (unpublished 
results), did not result in significantly elevated  pRab10Thr73 
phosphorylation levels. While the variances were higher for 
the control samples (standard deviation = 8.233 vs. 2.495 
(LRRK2 mutation carriers) and 2.640 (iPD)), there were no 
significant differences between the control, LRRK2 mutation 
carrier and iPD groups (Fig. 7b). We also tested whether 
biological sex had an overall effect on  pRab10Thr73 phos-
phorylation, but there was no significant difference between 
frontal cortex samples derived from female or male donors 
(data not shown). Total Rab10 levels displayed less variabil-
ity amongst frontal cortex samples and did not significantly 
differ between the groups (Fig. 7d). There was also a high 
degree of variability in Serine 935 phosphorylation levels of 
LRRK2 (Fig. 7f) and total LRRK2 levels (Fig. 7h) amongst 
samples, but overall, no significant difference between the 
LRRK2 mutation carrier, iPD and control groups. When 
comparing frontal and occipital lobe samples where matched 
pairs were available,  pRab10Thr73 phosphorylation tended 
to be lower in the occipital lobe than in the frontal lobe 
(with the exception of one G2019S mutation carrier (Col-3) 
where the levels in the occipital lobe were higher) (Fig. 7a) 
and total Rab10 levels were always lower in the occipital 
lobe samples (p = 0.0016) (Fig. 7c). For Serine 935 phos-
phorylation of LRRK2 (Fig. 7e), there was no significant dif-
ference between matched frontal and occipital lobe samples 
(paired t test, p = 0.3235), while total LRRK2 levels were 
significantly reduced in the occipital lobe when compared 
to matched frontal lobe samples (p = 0.001) (Fig. 7g). Addi-
tionally, we subjected the brain lysates to immunoblotting 
for the PPM1H phosphatase that counteracts LRRK2 signal-
ling by selectively dephosphorylating Rab proteins including 
Rab10 [2], but did not observe significant changes amongst 
samples or groups except for reduced levels in sample Col-3 
(suppl. Figure 4, online resource).
Fig. 6  Serine 935 phosphorylation of LRRK2 and total LRRK2 
levels in peripheral blood neutrophils. Normalized multiplexed 
pSerine935/total LRRK2 protein ratio (a) and normalized total 
LRRK2/GAPDH protein levels (b) of DMSO treated neutrophil 
lysates per group. Bars depict mean values with SD. Quantifica-
tions were based on the average value of two independent immuno-
blot runs. Differences between groups were calculated by one-way 
ANOVA followed by multiple comparisons where the mean of each 
column was compared against the mean of the other groups. There 
was a small, but statistically significant difference between the 
R1441G mutation carrier and iPD groups *p = 0.0454 for pSerine 
935/total LRRK2 while total LRRK2/GAPDH ratio remained largely 
unchanged between groups. When segregated by disease status, there 
was no significant difference between PD manifesting and non-mani-
festing mutation carriers for G2019S and R1441G (data not shown). 
For LRRK2 and pSerine935 quantification the higher molecular 
weight band representing full length LRRK2 was used
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Fig. 7  Quantification of pRab10Thr73 phosphorylation levels in 
post-mortem brain samples from LRRK2 mutation carriers, iPD 
and controls. Quantifications were based on the average value of 
two independent Western blotting experiments with duplicate sample 
loading. Quantification of phosphorylated  pRab10Thr73/total Rab10 
ratio and total Rab10 protein levels/GAPDH per sample with columns 
indicating means and SD (a, c) and per group for the frontal cortex 
samples (b, d), respectively. The same analysis was performed for 
LRRK2  Serine935  phosphorylation/total LRRK2 protein ratio and 
total LRRK2/GAPDH protein levels per sample (e, g) and per group 
for the frontal cortex samples (f, h), respectively. The R1441H muta-
tion carrier sample is marked with a white circle with black rim in the 




This is to date the largest study of LRRK2 dependent phos-
phorylation of its endogenous substrate  pRab10Thr73 in 
peripheral blood neutrophils in LRRK2 mutation carriers, 
controls and individuals with iPD. Our results include four 
key observations: (1) We show for the first time that LRRK2 
dependent  pRab10Thr73 phosphorylation as a surrogate 
marker for LRRK2 kinase activation status is significantly 
elevated in carriers of a specific pathogenic variant in the 
LRRK2 gene, namely the R1441G mutation in the ROC-COR 
GTPase domain. (2) This significant increase in  pRab10Thr73 
phosphorylation in LRRK2 R1441G mutation carriers is 
irrespective of clinical disease status and observed in non-
manifesting carriers as well as those diagnosed with PD. (3) 
We have not observed a statistically significant increase in 
LRRK2 dependent  pRab10Thr73 phosphorylation in carriers 
of the common G2019S mutation deploying two independent 
assays. (4) Furthermore, our explorative analysis of mark-
ers of the LRRK2 kinase pathway in human autopsy brain 
samples highlights important aspects and indeed problems 
with regards to feasibility, suitability and differences across 
different biomatrices. Additionally, we show that both Serine 
935 phosphorylation of LRRK2 as well as  pRab10Thr73 phos-
phorylation serve as biomarkers for LRRK2 kinase inhibition 
when using kinase inhibitors such as MLi-2. In this regard, 
it is important to note that pharmacokinetic properties vary 
depending on cellular context and assay readouts and that a 
relatively high concentration of MLi-2 was required to sup-
press Rab10 phosphorylation at Threonine 73 in peripheral 
blood neutrophils compared to previously reported IC50 of 
between 0.76 nM and 3.4 nM [11, 13].
Utilizing our facile and robust multiplex immunoblotting 
assay using sensitive phosphospecific antibodies against the 
Threonine 73 phospho-site of Rab10 that is phosphorylated 
by the LRRK2 kinase, a statistically significant increase of 
more than fourfold in  pRab10Thr73 phosphorylation levels 
was seen in LRRK2 R1441G mutation carriers when com-
pared to iPD, G2019S mutation carriers or controls. This 
increase was irrespective of disease status, and there was 
no significant difference between R1441G mutation car-
riers with and without PD manifestation. We also did not 
see an effect of female or male sex on LRRK2 dependent 
 pRab10Thr73 phosphorylation. This suggests that the effect on 
 pRab10Thr73 phosphorylation levels in circulating blood neu-
trophils is mainly driven by the underlying mutation itself 
rather than by the accompanying PD disease process. In 
future experiments it would be interesting to monitor larger 
numbers of participants and over time to better assess the 
utility of LRRK2 dependent  pRab10Thr73 phosphorylation 
as a marker of LRRK2 driven disease conversion or disease 
state.
Heterologous systems such as HEK293 overexpression of 
LRRK2 variants and genetic animal models with knock-in 
of LRRK2 mutations in the homozygous state have shown 
that the LRRK2 ROC and COR GTPases domain muta-
tions—including R1441G/H that suppress GTPases activity 
and promote GTP binding—mediate a 3 to 4-fold increase 
in LRRK2 kinase activity [38, 39] while LRRK2 kinase 
domain mutations such as G2019S increase LRRK2 kinase 
activity only modestly, typically under twofold (reviewed 
in [40]) by domain disruption. In our experiments, we did 
not observe a statistically significant increase in  pRab10Thr73 
phosphorylation levels in 21 LRRK2 G2019S mutation car-
riers despite promising results from a previous much smaller 
study of  pRab10Thr73 phosphorylation stoichiometry in neu-
trophils from 4 G2019S mutation carriers in comparison to 4 
non-mutation carriers [21]. While there was good correlation 
between our two assays which allowed for independent con-
firmation of our results, the potentially more sensitive mass-
spectrometry assay did not yield any additional information 
with regards to LRRK2 dependent  pRab10Thr73 phosphoryla-
tion levels. Given that the LRRK2 G2019S mutation induces 
an under twofold enhancement of  pRab10Thr73 phosphoryla-
tion in homozygosity, one would expect a relative reduction 
to < 1.5-fold in heterozygosity. We, therefore, conclude that 
the effect of the LRRK2 G2019S mutation in heterozygo-
sity as with the participants in our study coupled with the 
biological variation in between human samples is too small 
to accurately yield a significant difference by quantitative 
multiplexed immunoblotting or even more sensitive mass-
spectrometry methodologies. On the other hand, measur-
ing  pRab10Thr73 phosphorylation levels using our relatively 
straightforward immunoblotting assay [12] may be attractive 
for researchers without access to a mass-spectrometry facil-
ity as the data obtained was similar in quality and resolution 
to the mass-spectrometry data.
A recent study found a statistically significant decrease in 
Serine 935 phosphorylation of LRRK2 in human peripheral 
blood mononuclear cells (PBMCs) derived from LRRK2 
G2019S mutation carriers with PD but not G2019S non-
manifesting mutation carriers when compared to iPD [35]. 
Here, we have not observed a reduction in Serine 935 phos-
phorylation levels in G2019 mutation carriers with PD 
in comparison to iPD or in fact in comparison to any of 
the other groups. However, the differences in biomatrix—
PBMCs vs neutrophils—and assay methodology—digital 
immunoassay vs quantitative multiplexed immunoblot-
ting—may account for this discrepancy. For example, neu-
trophils represent a homogenous cell population with high 
LRRK2 expression, but their intrinsically very active serine 
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proteases appear to affect disproportionately high molecular 
weight species such as LRRK2 (288 kDa) with resulting par-
tial LRRK2 degradation [11]. This particular problem could 
be addressed using peripheral blood monocytes for LRRK2 
pathway analysis as described by us previously [27]. It 
would, therefore, be of interest to expand and compare Ser-
ine 935 phosphorylation of LRRK2 across different periph-
eral blood cell populations including monocytes and addi-
tional patient cohorts. What we did observe was a reduction 
in Serine 935 phosphorylation in LRRK2 R1441G mutation 
carriers when compared to iPD, but not when segregated by 
clinical status or in comparison to LRRK2 G2019S mutation 
carriers or controls, a finding that is consistent with previous 
studies [9, 40]. Importantly, our results also clearly show 
that LRRK2 Serine 935 phosphorylation is not a marker of 
LRRK2 kinase activity.
pRab10Thr73 phosphorylation has previously been shown 
to be elevated in substantia nigra of patients with iPD 
when compared to controls [8]. While we were interested 
in extending our analysis to post-mortem brain samples of 
LRRK2 mutation carriers and iPD in comparison to con-
trols and assess its correlation with peripheral blood neu-
trophils, we were unable to obtain substania nigra samples, 
but only frontal and additionally occipital cortex samples in 
some. While total Rab10 protein levels were relatively sta-
ble amongst all samples, the  pRab10Thr73 phosphorylation 
signal was not or hardly detectable in the majority of cases 
and otherwise variable irrespective of genotype and clini-
cal disease status. In particular, we did not observe signifi-
cant  pRab10Thr73 hyperphosphorylation in the one LRRK2 
R1441H mutation carrier sample which biochemically 
should have the same augmenting effect on LRRK2 depend-
ent  pRab10Thr73 phosphorylation as the R1441G mutation 
[39]. While the LRRK2 total protein and Serine 935 phos-
phorylation of LRRK2 signals could be detected there was 
again a large degree of disparity for Serine 935 phosphoryla-
tion between samples. Overall, the main finding was that 
there was high variability amongst individual samples in 
all parameters that we analysed, and this is consistent with 
our previous study of human brain cingulate cortex samples 
from 23 controls and 28 individuals with iPD [24].
While it would be worthwhile to expand the analysis of 
 pRab10Thr73 phosphorylation in autopsy brain material to a 
larger number of cases, in particular of carriers of R1441 
hotspot or the VPS35 D620 mutations, there are important 
factors to consider such as circumstances and cause of death 
and post-mortem interval that may affect tissue quality and 
in particular stability of posttranslational phosphorylation 
modifications [22]. Another concern above and beyond the 
regional variation of brain tissue is its heterogeneity in terms 
of cellular composition which is not taken into account in 
the assay deployed in this study. We, therefore, conclude 
that measuring  pRab10Thr73 phosphorylation in post-mortem 
brain lysates is uninformative mainly due to the instability 
of posttranslational modifications.
In conclusion our findings add compelling evidence that 
interrogating in vivo LRRK2 dependent  pRab10Thr73 phos-
phorylation in human peripheral blood neutrophils is a spe-
cific, robust and promising biomarker for significant LRRK2 
kinase hyperactivation, as with the LRRK2 R1441G mutation 
or as previously demonstrated with the VPS35 D620N muta-
tion [27]. Further work is required to explore additional read-
outs including phosphorylation levels of other RabGTPase 
substrates of the LRRK2 kinase [34], assays and biomatrices 
that would allow detection of more modest LRRK2 kinase 
activation as with the LRRK2 G2019S mutation and possibly 
in individuals with iPD. We envision that our assays will 
be used alongside other markers of the LRRK2 signalling 
and PD associated pathways across different biomatrices and 
importantly longitudinally to possibly delineate integrated 
markers for disease conversion and PD progression.
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